January 28, 2000, and related determinations.

**EFFECTIVE DATE:** February 1, 2000.

#### FOR FURTHER INFORMATION CONTACT:

Madge Dale, Response and Recovery Directorate, Federal Emergency Management Agency, Washington, DC 20472, (202) 646–3772.

**SUPPLEMENTARY INFORMATION:** The notice of a major disaster for the State of Georgia is hereby amended to include the following areas among those areas determined to have been adversely affected by the catastrophe declared a major disaster by the President in his declaration of January 28, 2000:

Banks, Barrow, Bartow, Carroll, Chattooga, Cherokee, Cobb, Dawson, DeKalb, Douglas, Elbert, Fannin, Floyd, Forsyth, Franklin, Fulton, Gilmer, Gordon, Gwinnett, Habersham, Hall, Hart, Lumpkin, Newton, Oconee, Paulding, Pickens, Rabun, Rockdale, Stephens, Union, Walker, White, and Wilkes for utilities (Category F) under the Public Assistance program (already designated for debris removal (Category A) and emergency protective measures, (Category B), including direct Federal assistance, under the Public Assistance program).

(The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used for reporting and drawing funds: 83.537, Community Disaster Loans; 83.538, Cora Brown Fund Program; 83.539, Crisis Counseling; 83.540, Disaster Legal Services Program; 83.541, Disaster Unemployment Assistance (DUA); 83.542, Fire Suppression Assistance; 83.543, Individual and Family Grant (IFG) Program; 83.544, Public Assistance Grants; 83.545, Disaster Housing Program; 83.548, Hazard Mitigation Grant Program.)

#### Lacy E. Suiter,

Executive Associate Director, Response and Recovery Directorate.

[FR Doc. 00–2808 Filed 2–7–00; 8:45 am]

BILLING CODE 6718-02-P

### FEDERAL RESERVE SYSTEM

## Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 3, 2000.

- A. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198–0001:
- 1. Central Financial Corporation, Hutchinson, Kansas; to acquire 8.34 percent of the voting shares of NorthStar Bancshares, Inc., Riverside, Missouri, and thereby acquire shares of NorthStar Bank, N.A., Kansas City, Missouri.
- B. Federal Reserve Bank of San Francisco (Maria Villanueva, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105–1579:
- 1. FNB Bancorp, Layton, Utah; to become a bank holding company by acquiring 100 percent of the voting shares of First National Bank of Layton, Layton, Utah.

Board of Governors of the Federal Reserve System, February 2, 2000.

#### Robert deV. Frierson,

Associate Secretary of the Board.
[FR Doc. 00–2720 Filed 2–7–00; 8:45 am]
BILLING CODE 6210–01–P

### FEDERAL RESERVE SYSTEM

#### **Sunshine Act Meeting**

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System.

**TIME AND DATE:** 9 a.m., Friday, February 11, 2000.

**PLACE:** Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW, Washington, DC 20551.

STATUS: Closed.

#### MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions)

involving individual Federal Reserve System employees.

2. Any matters carried forward from a previously announced meeting.

**CONTACT PERSON FOR MORE INFORMATION:** Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: February 3, 2000.

#### Robert deV. Frierson.

Associate Secretary of the Board.
[FR Doc. 00–2890 Filed 2–3–00; 4:54 pm]
BILLING CODE 6210–01–P

#### **GENERAL ACCOUNTING OFFICE**

#### Advisory Council on Government Auditing Standards; Notice of Meeting

The Advisory Council on Government Auditing Standards will meet Monday, February 28, 2000, from 8:30 a.m. to 5:00 p.m., and Tuesday, February 29, 2000, from 8:30 a.m. to 12:15 p.m., in room 7C13 of the General Accounting Office building, 441 G Street, NW., Washington, DC.

The Advisory Council on Government Auditing Standards will hold a meeting to discuss issues that may impact government auditing standards. Any interested person may attend the meeting as an observer. Council discussions and reviews are open to the public.

For further information contact: Marcia Buchanan, Assistant Director, Government Auditing Standards, AIMD, 202–512–9321.

#### Marcia B. Buchanan,

Assistant Director.

[FR Doc. 00–2859 Filed 2–7–00; 8:45 am]

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Office of the Secretary

# Meeting of the Secretary's Advisory Committee on Genetic Testing

**AGENCY:** Office of the Secretary, DHHS. **ACTION:** Notice of meeting.

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Secretary's Advisory Committee on Genetic Testing (SACGT), U.S. Public Health Service. The meeting will be held at the International Trade Center, Polaris Ballroom, 1300 Pennsylvania Avenue, NW, Washington, DC 20004, starting on February 24, 2000, at approximately 9:00 a.m. and will recess at approximately 5:30 p.m. The meeting will reconvene on February 25, 2000, at approximately 8:00 a.m. and will adjourn at approximately 5:00 p.m. The meeting will be open to the public. Attendance by the public will be limited by the space available. The committee will review public comments received in response to A Public Consultation on Oversight of Genetic Tests published in the Federal Register on December 1, 1999 (64 FR 67273), and work toward the development of final recommendations on the oversight of genetic testing. A limited period of time will be provided for public comment, and individuals interested in participating in the public comment period should contact Ms. Sarah Carr, SACGT Executive Secretary, as shown

Under authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services (DHHS) established the SACGT to advise and make recommendations to the Secretary through the Assistant Secretary for Health on all aspects of the development and use of genetic tests. The SACGT is directed to: (1) Recommend policies and procedures for the safe and effective incorporation of genetic technologies into health care; (2) assess the effectiveness of existing and future measures for oversight of genetic tests; (3) and identify research needs related to the Committee's purview.

Further information about the SACGT is available at the following web site: http://www4.od.nih.gov/oba/sacgt.htm. If you wish to attend, please register through the web site. A draft meeting agenda will be posted to the web site prior to the meeting. Individuals who wish to provide public comments should notify Ms. Carr, by telephone at 301-496-9838 or E-mail at sc112c@nih.gov as soon as possible and provide a copy of their remarks to Ms. Carr by February 15, 2000. Those who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Ms. Carr at 301-496-9838. The SACGT office is located at 6000 Executive Boulevard, Suite 302, Bethesda, Maryland 20892.

Dated: February 3, 2000.

#### Sarah Carr,

Executive Secretary, SACGT.
[FR Doc. 00–2906 Filed 2–7–00; 8:45 am]
BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### **Notice of Meeting**

Office of the Director, Centers for Disease Control and Prevention (CDC), announces the following meeting:

Name: Guide to Community Preventive Services (GCPS) Task Force Meeting.

Times and Dates: 9 a.m.-5:30 p.m., February 9, 2000; 8 a.m.-3:30 p.m., February 10, 2000.

Place: The Renaissance Waverly Hotel, 2450 Galleria Parkway, Atlanta, Georgia 30339, telephone (770) 953–4500.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 40 people.

Purpose: The mission of the Task Force is to develop and publish a Guide to Community Preventive Services, which is based on the best available scientific evidence and current expertise regarding essential public health services and what works in the delivery of those services.

Matters to be Discussed: Agenda items include: a briefing of administrative activities in the Community Guide Branch, recommendation approvals for the Oral Health and Tobacco Chapters, updates for the following chapters: Diabetes, Cancer, Motor Vehicle Occupant Injuries, Mental Health, Physical Activity, Nutrition, Sexual Behavioral, Alcohol, Violence Prevention and Sociocultural Environment, an update on the Economic Evaluation and a discussion of actions items for the next quarter.

Agenda items are subject to change as priorities dictate.

Contact Person for Additional Information: Stephanie Zaza, M.D., M.P.H., Chief, CPS Guide Development Activity, Division of Prevention Research and Analytic Methods, Epidemiology Program Office, CDC, 4770 Buford Highway, M/S K–73, Atlanta, Georgia 30341, telephone 770/488–8189.

Persons interested in reserving a space for this meeting should call 770/488–8189 by close of business on February 7, 2000.

The Director, Management Analysis and Services office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00–2899 Filed 2–7–00; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **Food and Drug Administration**

[Docket No. 99N-0671]

# Bestblood, Ltd.; Revocation of U.S. License No. 1116

AGENCY: Food and Drug Administration,

HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of the establishment license (U.S. License No. 1116) and product licenses (the licenses) issued to Bestblood, Ltd., doing business as Optimum Healthcare, Inc., for the manufacture of Whole Blood, Red Blood Cells, Red Blood Cells Frozen, Whole Blood CPD, Red Blood Cells Deglycerolized, and Whole Blood CPDA-1. Bestblood, Ltd., did not respond to a notice of opportunity for a hearing on a proposal to revoke its licenses.

**DATES:** The revocation of the establishment license (U.S. License No. 1116) and product licenses is effective February 8, 2000.

### FOR FURTHER INFORMATION CONTACT:

Joseph L. Okrasinski, Jr., Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD. 20852–1448, 301–827–

SUPPLEMENTARY INFORMATION: FDA is revoking the establishment license (U.S. License No. 1116) and product licenses issued to Bestblood, Ltd., doing business as Optimum Healthcare, Inc., 239 Randall St., San Francisco, CA 94131, for the manufacture of Whole Blood, Red Blood Cells, Red Blood Cells Frozen, Whole Blood CPD, Red Blood Cells Deglycerolized, and Whole Blood CPDA-1. Proceedings to revoke the licenses were initiated because an attempted inspection of the facility by FDA, as required under 21 CFR 600.21, revealed that the firm was no longer in operation.

In a certified, return-receipt letter dated June 16, 1997, FDA notified the firm that the attempt to conduct an inspection at Bestblood, Ltd., 239 Randall St., San Francisco, CA 94131 was unsuccessful because the facility was apparently no longer in operation and requested that the firm notify FDA in writing of the firm's status. This letter was sent to 239 Randall St., San Francisco, CA 94131, and also to P.O. Box 843, Cupertino, CA 95054–0843,